INT120514

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1999
Last Reported 2006
Negated 0
Speculated 1
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.19
Pain Relevance 1.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Otc) cytoplasm (Otc)
Otc (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 23 99.84 Very High Very High Very High
aspirin 96 97.96 Very High Very High Very High
Arthritis 4 93.58 High High
Migraine 1 89.84 High High
headache 1 89.28 High High
Inflammation 2 85.04 High High
Pain 2 61.76 Quite High
Bioavailability 1 54.48 Quite High
Paracetamol 4 18.96 Low Low
nud 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ornithine Transcarbamylase Deficiency 2 100.00 Very High Very High Very High
Toxicity 1 95.30 Very High Very High Very High
Arthritis 4 93.58 High High
Disease 5 93.16 High High
Headache 2 89.84 High High
INFLAMMATION 4 85.04 High High
Pain 2 61.76 Quite High
Hemorrhage 27 51.52 Quite High
Ulcers 4 51.16 Quite High
Dental Caries 11 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nitric oxide synthesis in ornithine transcarbamylase deficiency: possible involvement of low no synthesis in clinical manifestations of urea cycle defect.
Negative_regulation (deficiency) of Gene_expression (synthesis) of ornithine transcarbamylase associated with ornithine transcarbamylase deficiency
1) Confidence 0.41 Published 2004 Journal J. Pediatr. Section Title Doc Link 15289781 Disease Relevance 0.37 Pain Relevance 0.18
Other authors have recently reached the same conclusion for OTC
Negative_regulation (reached) of Gene_expression (conclusion) of OTC
2) Confidence 0.37 Published 2001 Journal BMC Clin Pharmacol Section Body Doc Link PMC32172 Disease Relevance 0.10 Pain Relevance 0.41
 ; (c) reliability of composition, and reproducibility (especially of natural products); (d) general safety; (e) interactions with other medications; (f) honest labelling (in the absence of stricter guidelines).A particularly difficult problem is to know how to recognise a 'drug of choice', particularly for such a multi-faceted disease as chronic arthritis, when there is so little information about the actual pharmacology/potential toxicity of these OTC products in the standard drug compendia and other readily available reference texts.This grey area can only be illuminated by (i) further introduction (and enforcement) of adequate standards/quality controls for products offered OTC; (ii) earliest prosecution of clinical trials to supercede unverified testimonial claims; (iii) appropriate funding to research/establish basic pharmacology of the active principles.In summary, more research, more regulation, and more realistic investment will be required to dispel present uncertainty about which non-NSAID drugs/nutriceuticals are indeed effective against arthritis/other forms of inflammation, and which are not.
Negative_regulation (offered) of Gene_expression (prosecution) of OTC associated with toxicity, inflammation, cinod, disease and arthritis
3) Confidence 0.23 Published 1999 Journal Inflammopharmacology Section Abstract Doc Link 17638094 Disease Relevance 0.72 Pain Relevance 0.46
First, it is not in the FDA's regulatory purview to assure that OTC drug products are as clinically effective as possible, only that they are clinically effective and safe.
Spec (possible) Negative_regulation (effective) of Gene_expression (products) of OTC
4) Confidence 0.18 Published 2006 Journal BMC Oral Health Section Body Doc Link PMC2147065 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox